Sign in or create an account to add this stock to your watchlist.
About TrovaGene (NASDAQ:TROV)
Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570
Debt
Debt-to-Equity RatioN/A
Current Ratio2.03
Quick Ratio2.03
Price-To-Earnings
Trailing P/E Ratio-0.48
Forward P/E Ratio-0.99
P/E GrowthN/A
Sales & Book Value
Annual Sales$500,000.00
Price / Sales30.58
Cash FlowN/A
Price / CashN/A
Book Value$0.08 per share
Price / Book3.22
Profitability
EPS (Most Recent Fiscal Year)($0.54)
Net Income$-24,900,000.00
Net Margins-3,861.57%
Return on Equity-342.47%
Return on Assets-134.39%
Miscellaneous
Employees17
Outstanding Shares59,380,000
TrovaGene (NASDAQ:TROV) Frequently Asked Questions
What is TrovaGene's stock symbol?
TrovaGene trades on the NASDAQ under the ticker symbol "TROV."
How were TrovaGene's earnings last quarter?
TrovaGene Inc (NASDAQ:TROV) announced its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.03. The medical research company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 342.47% and a negative net margin of 3,861.57%. View TrovaGene's Earnings History.
When is TrovaGene's next earnings date?
What price target have analysts set for TROV?
3 brokerages have issued 12-month price targets for TrovaGene's shares. Their forecasts range from $1.00 to $4.00. On average, they expect TrovaGene's stock price to reach $2.50 in the next twelve months. View Analyst Ratings for TrovaGene.
What are Wall Street analysts saying about TrovaGene stock?
Here are some recent quotes from research analysts about TrovaGene stock:
- 1. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (5/3/2018)
- 2. Maxim Group analysts commented, "Trovagene announces the initiation of its Phase 2 clinical trial, evaluating the combination of PCM-075 and Zytiga in patients with metastatic Castration- Resistant Prostate Cancer (mCRPC). The study will enroll n=25 patients with mCRPC who are showing early signs of disease progression while on abiraterone/prednisone therapy and will evaluate the proportion of patients achieving disease control after 12 weeks of study treatment. Trovagene still needs to raise capital. The company raised $4.5M in December last year, not enough to achieve critical mass. We downgraded the stock (Nov. 10, 2017) on anticipation that the raise would be dilutive. So while we fundamentally believe in PCM-075, a weak balance sheet still needs to be addressed before we could be more constructive on the outlook for the company." (1/24/2018)
Who are some of TrovaGene's key competitors?
Some companies that are related to TrovaGene include BioCardia (BCDA), Champions Oncology (CSBR), BiondVax (BVXV), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Microbot Medical (MBOT), Proteon Therapeutics (PRTO), Vical (VICL), Vaxart (VXRT), Oncobiologics (ONS), aTyr Pharma (LIFE), Neuralstem (CUR), Genetic Technologies (GENE), Titan Pharmaceuticals (TTNP) and Windtree Therapeutics (WINT).
Who are TrovaGene's key executives?
TrovaGene's management team includes the folowing people:
- Mr. William J. Welch, CEO & Director (Age 56)
- Dr. Mark Erlander, Chief Scientific Officer (Age 58)
- Dr. Karsten Schmidt Ph.D., Chief Technology Officer (Age 56)
- Ms. Elizabeth Anderson CPA, VP of Fin. and Admin.
- Mr. George Samuel J.D., VP & Gen. Counsel
Has TrovaGene been receiving favorable news coverage?
Press coverage about TROV stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. TrovaGene earned a news sentiment score of 0.05 on Accern's scale. They also assigned news headlines about the medical research company an impact score of 47.46 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of TrovaGene?
Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TrovaGene's stock price today?
One share of TROV stock can currently be purchased for approximately $0.2575.
How big of a company is TrovaGene?
TrovaGene has a market capitalization of $15.87 million and generates $500,000.00 in revenue each year. The medical research company earns $-24,900,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis. TrovaGene employs 17 workers across the globe.
How can I contact TrovaGene?
TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]
MarketBeat Community Rating for TrovaGene (TROV)
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
TrovaGene (NASDAQ:TROV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for TrovaGene in the last 12 months. Their average twelve-month price target is $2.50, suggesting that the stock has a possible upside of 870.87%. The high price target for TROV is $4.00 and the low price target for TROV is $1.00. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Hold | Hold |
| Consensus Rating Score: | 2.67 | 2.67 | 2.25 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $2.50 | $2.50 | $3.70 | $4.60 |
| Price Target Upside: | 870.87% upside | 557.89% upside | 1,133.33% upside | 576.47% upside |
TrovaGene (NASDAQ:TROV) Consensus Price Target History
TrovaGene (NASDAQ:TROV) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
TrovaGene (NASDAQ:TROV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
TrovaGene (NASDAQ TROV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.30%
Institutional Ownership Percentage: 4.52%
TrovaGene (NASDAQ TROV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 9/5/2017 | Stanley Tennant | Director | Sell | 8,334 | $0.69 | $5,750.46 | 209,394 |  |
| 12/19/2016 | Stanley Tennant | Director | Buy | 10,000 | $2.10 | $21,000.00 | 217,728 | |
| 12/16/2016 | Stanley Tennant | Director | Buy | 14,966 | $2.00 | $29,932.00 | 207,728 | |
| 12/16/2016 | William J Welch | CEO | Buy | 4,750 | $2.09 | $9,927.50 | 2,500 | |
| 12/14/2016 | Mark Erlander | Insider | Buy | 5,000 | $2.08 | $10,400.00 | 5,000 | |
| 8/12/2015 | Antonius Schuh | CEO | Buy | 20,000 | $5.45 | $109,000.00 | | |
| 8/12/2015 | Stanley Tennant | Director | Buy | 10,000 | $6.06 | $60,600.00 | | |
| 8/12/2015 | Steve Zaniboni | CFO | Buy | 15,000 | $5.43 | $81,450.00 | | |
| 7/17/2015 | Bridger Management, Llc | Major Shareholder | Buy | 140,000 | $8.75 | $1,225,000.00 | | |
| 4/2/2015 | Bridger Management, Llc | Major Shareholder | Buy | 300,000 | $6.90 | $2,070,000.00 | | |
| 2/27/2015 | Bridger Management, Llc | Major Shareholder | Buy | 263,286 | $5.36 | $1,411,212.96 | | |
| 2/6/2015 | Bridger Management, Llc | Major Shareholder | Buy | 444,444 | $4.50 | $1,999,998.00 | | |
| 6/9/2014 | Steve Zaniboni | CFO | Buy | 6,329 | $3.95 | $24,999.55 | | |
| 9/3/2013 | Thomas Phd Adams | Director | Sell | 19,200 | $8.19 | $157,248.00 | | |
| 11/30/2012 | Stanley Tennant | Director | Buy | 25,000 | $4.82 | $120,500.00 | | |
| 8/20/2012 | Gabriel Cerrone | Director | Buy | 7,800 | $2.35 | $18,330.00 | | |
| 8/16/2012 | Gabriel Cerrone | Director | Buy | 15,000 | $2.24 | $33,600.00 | | |
(Data available from 1/1/2013 forward)
TrovaGene (NASDAQ TROV) News Headlines
| Source: |
|
TrovaGene (NASDAQ:TROV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
TrovaGene (NASDAQ:TROV) Income Statement, Balance Sheet and Cash Flow Statement
TrovaGene (NASDAQ TROV) Stock Chart for Thursday, May, 24, 2018
Loading chart…
